A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/00 (2006.01) A61K 38/21 (2006.01)
Patent
CA 2302834
The present invention provides the use of IFN-.alpha. in association with Amantadine for the manufacture of medicaments for the treatment of chronic hepatitis C infections. The present invention also provides medicaments containing the IFN-.alpha. and Amantadine as a combined preparation for simultaneous, separate or sequential use in therapy of chronic hepatitis C infections. The present invention further provides a method for treating chronic hepatitis C infections in patients in need of such treating comprising administering an amount of IFN-.alpha. in association with an amount of Amantadine effective to treat hepatitis C.
La présente invention concerne l'utilisation d'interféron-alpha (IFN-.alpha.) associé à l'amantadine, dans la fabrication de médicaments destinés au traitement d'infections par le virus de l'hépatite C chronique, et elle concerne également des médicaments contenant l'IFN-.alpha. et l'amantadine en tant que préparation combinée destinée à un emploi simultané, séparé ou séquentiel dans la thérapie d'infections par le virus de l'hépatite C chronique. L'invention concerne encore une méthode de traitement de telles infections chez des patients nécessitant un tel traitement, cette méthode consistant à administrer une dose d'IFN-.alpha. associée à une dose d'amantadine qui soit efficace pour traiter l'hépatite C.
Zahm Friederike
F. Hoffmann-La Roche Ag
Gowling Lafleur Henderson Llp
LandOfFree
Use of ifn-alpha and amantadine for the treatment of chronic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of ifn-alpha and amantadine for the treatment of chronic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ifn-alpha and amantadine for the treatment of chronic... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1623040